What are the treatment options for perimenopause?

Perimenopause Treatment

First-Line Treatment Recommendation

For perimenopausal women under 60 years old or within 10 years of menopause onset experiencing bothersome vasomotor symptoms (hot flashes, night sweats), initiate transdermal estradiol 50 μg daily patches (applied twice weekly) combined with micronized progesterone 200 mg orally at bedtime for women with an intact uterus. 1, 2

---

Pre-Treatment Screening: Absolute Contraindications

Before initiating any hormonal therapy, screen for the following absolute contraindications 1, 3:

• History of breast cancer or hormone-sensitive malignancies 1, 3
• Active or history of venous thromboembolism (DVT/PE) or stroke 1, 3
• Coronary heart disease or myocardial infarction 1, 3
• Active liver disease 1, 3
• Antiphospholipid syndrome or positive antiphospholipid antibodies 1, 3
• Unexplained abnormal vaginal bleeding 1, 3

If any contraindication exists, proceed directly to non-hormonal options. 1, 3

---

Hormonal Treatment Algorithm

For Women WITH Intact Uterus

Transdermal estradiol 50 μg/day patches (changed twice weekly) PLUS micronized progesterone 200 mg orally at bedtime 1, 2

• Transdermal delivery bypasses hepatic first-pass metabolism, reducing cardiovascular and thromboembolic risks compared to oral formulations 1, 2
• Micronized progesterone is preferred over medroxyprogesterone acetate due to lower rates of venous thromboembolism and breast cancer risk 2
• Never use estrogen without progestin in women with intact uterus—this increases endometrial cancer risk by 90% 1, 2

For Women WITHOUT Uterus (Post-Hysterectomy)

Transdermal estradiol 50 μg/day patches alone (no progestin needed) 1, 2

• Estrogen-alone therapy shows NO increased breast cancer risk and may even be protective (RR 0.80) 2
• Reduces vasomotor symptom frequency by approximately 75% 2

---

Non-Hormonal Treatment Options

For Women Who Cannot Take Hormone Therapy

First-line non-hormonal medications 1, 4:

• SNRIs (venlafaxine): Decrease hot flash intensity and severity by 40-65% 1
• SSRIs: Effective for vasomotor symptoms but avoid in women on tamoxifen due to drug interactions 1
• Gabapentin: Effective alternative for reducing hot flashes 1
• Neurokinin B antagonists: Newer class showing promise for vasomotor symptoms, sleep, and mood issues 4

Lifestyle modifications 1:

• Rhythmic breathing exercises 1
• Regular exercise 1
• Avoiding known triggers (caffeine, alcohol, spicy foods, hot environments) 1
• Environmental cooling strategies 1

---

Genitourinary Symptom Management

First-Line Approach

Vaginal moisturizers and lubricants 1, 3

• Reduce symptom severity by up to 50% 1, 3
• No systemic absorption—safe for all patients including those with hormone-sensitive cancers 1, 3

Second-Line for Persistent Symptoms

Low-dose vaginal estrogen preparations (rings, suppositories, or creams) 1, 2

• Improve genitourinary symptoms by 60-80% with minimal systemic absorption 1, 2
• Avoid in patients with hormone-sensitive cancers 1, 3
• No systemic progestin needed for low-dose vaginal estrogen 2

---

Risk-Benefit Profile of Hormone Therapy

Absolute Risks Per 10,000 Women Taking Estrogen-Progestin for 1 Year 1, 2:

Risks:

• 7 additional coronary heart disease events 1, 2
• 8 more strokes 1, 2
• 8 more pulmonary emboli 1, 2
• 8 more invasive breast cancers 1, 2

Benefits:

• 6 fewer cases of colorectal cancer 1, 2
• 5 fewer hip fractures 1, 2
• 30-50% reduction in osteoporosis and fractures 1, 2
• 75% reduction in vasomotor symptom frequency 2

The progestin component drives breast cancer risk, not estrogen alone—estrogen-only therapy in women without a uterus shows reduced breast cancer risk. 2

---

Duration and Monitoring

Use the lowest effective dose for the shortest duration necessary 1, 2

• Initiate therapy when symptoms begin during perimenopause—do not delay until postmenopause 2
• Reassess necessity annually 2
• Attempt dose reduction or discontinuation once symptoms improve 2
• Breast cancer risk increases significantly with duration beyond 5 years 2
• Never initiate HRT solely for chronic disease prevention—harms exceed benefits for this indication 1, 2, 3

---

Special Populations

Premature Ovarian Insufficiency (Before Age 45)

Initiate HRT immediately at diagnosis regardless of symptoms 1, 2

• Continue until at least age 51 (average age of natural menopause), then reassess 1, 2
• Prevents long-term cardiovascular, bone, and cognitive consequences 2
• Risk-benefit profile is highly favorable in this population 2

Women Over 60 or More Than 10 Years Past Menopause

Avoid initiating oral estrogen—associated with excess stroke risk 1, 2, 3

• If HRT is necessary, use transdermal formulations at the lowest possible dose 2
• Consider non-hormonal alternatives first 1, 3

Women With History of Breast Cancer

Avoid all systemic hormone therapy 1, 3

• Use non-hormonal options: SSRIs, SNRIs, gabapentin, neurokinin B antagonists 1, 3, 4
• Vaginal moisturizers and lubricants are safe for genitourinary symptoms 1, 3
• Do not use vaginal estrogen in hormone-sensitive cancers 1, 3

Women With Non-Hormone-Sensitive Cancers

May consider HRT after oncology consultation 1, 3

• Reassess at average age of menopause (51 years) 1, 3

---

Critical Pitfalls to Avoid

• Never use estrogen without progestin in women with intact uterus—increases endometrial cancer risk by 90% 1, 2
• Never initiate HRT solely for osteoporosis or cardiovascular disease prevention—use bisphosphonates, denosumab, or SERMs instead 1, 2, 3
• Never use oral estrogen in women over 60 or more than 10 years past menopause—excess stroke risk 1, 2, 3
• Do not assume all HRT regimens carry equal risk—progestin type and route of administration significantly affect risk profile 1, 2
• Avoid SSRIs in women on tamoxifen due to drug interactions 1
• Do not use custom compounded bioidentical hormones or pellets—lack safety and efficacy data 2